The Ashton Lecture. Uveal melanoma: The past, the present and the future

Eye

Volumn 11, Issue 2, 1997, Pages 255-264

  Rennie, Ian G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cytogenetics; Immunology; Oncogenes; Uveal melanoma

Indexed keywords

CANCER SURVIVAL; CILIARY BODY; CONFERENCE PAPER; HUMAN; LASER COAGULATION; METASTASIS; METASTASIS POTENTIAL; TUMOR IMMUNOLOGY; UVEA MELANOMA;

EID: 0030927751     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.1997.61     Document Type: Conference Paper

References (98)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma [review]. Surv Ophthalmol 1988;32:239-51.
2. Fuchs E. Das Sarcom des Uvealtractus. Vienna, 1882.
3. Shields JA, Shields CL. Intraocular tumours. Philadelphia: WB Saunders, 1992:171-205.
4. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol 1930;14:145-56.
5. Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol 1966;50:147-55.
6. Packer S, Rotman M, Fairchild RG, et al. Irradiation of choroidal melanoma with iodine-125 ophthalmic plaque. Arch Ophthalmol 1980;98:1453-7.
7. Garretson BR, Robertson DM, Earle JD. Choroidal melanoma treatment with iodine-125 brachytherapy. Arch Ophthalmol 1987;105:1394-7.
8. Packer S. Iodine-125 radiation of posterior uveal melanoma. Ophthalmology 1987;94:1621-6.
9. Gragoudas ES, Goitein M, Koehler AM, et al. Proton irradiation of choroidal melanomas: preliminary results. Arch Ophthalmol 1978;96:1583-91.
10. Gragoudas ES, Goitein M, Verhey L, Munzenreider J, Urie M, Suit H, et al. Proton beam irradiation of uveal melanomas: results of 51/2-year study. Arch Ophthalmol 1982;100:928-34.
11. Gragoudas ES, Egan KM, Saornil MA, Walsh SM, Albert DM, Seddon JM. The time course of irradiation changes in proton beam-treated uveal melanomas. Ophthalmology 1993;100:1555-9.
12. Rennie IG, Forster D, Kemeny A, Walton L, Kunkler I. The use of single fraction Leksell stereotactic radiosurgery in the treatment of uveal melanoma. Acta Ophthalmol (Copenh) 1996;74:558-62.
13. Meyer-Schwickerath G. The preservation of vision by treatment of intraocular tumours with light coagulation. Arch Ophthalmol 1961;66:458-66.
14. Barr CC, Norton EWD. Recurrence of choroidal melanoma after photocoagulation therapy. Arch Ophthalmol 1983;101:1737.
15. Peyman GA, Apple DJ. Local excision of choroidal malignant melanoma. Arch Ophthalmol 1974;92: 216-18.
16. Peyman GA, Axelrod AJ, Graham RO. Full-thickness eye wall resection. An experimental approach for treatment of choroidal melanoma: evaluation of cryotherapy, diathermy and photocoagulation. Arch Ophthalmol 1974;91:219-22.
17. Foulds WS. The local excision of choroidal melanomata. Trans Ophthalmol Soc UK 1973;93:343-6.
18. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology 1988;95:1000-4.
19. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:123-32.
20. Pach JM, Robertson DM. Metastasis from untreated uveal melanomas. Arch Ophthalmol 1986;104:1624-5.
21. Wagoner MD, Albert DM. The incidence of metastases from untreated ciliary body and choroidal melanoma. Arch Ophthalmol 1982;100:939-40.
22. Zimmerman LE, Mclean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol 1978;62:420-5.
23. Fraunfelder FT, Boozman FW, Wilson RS, et al. Notouch technique for intraocular malignant melanomas. Arch Ophthalmol 1977;95:1616-20.
24. Manschot WA, van Perperzeel HA. Choroidal melanoma. Enucleation or observation? A new approach. Arch Ophthalmol 1980;98:71-7.
25. Shields JA, Augsburger JJ, Donoso LA, Bernardino VB Jr, Portenar M. Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years. Am J Ophthalmol 1985;100:666-8.
26. Flocks M, Gerende JH, Zimmerman LE. The size and shape of malignant melanomas of the choroid and ciliary body in relation to prognosis and histologic characteristics. Trans Am Acad Ophthalmol Otolaryngol 1955;59:740-58.
27. Davidorf FH, Lang JR. Small malignant melanomas of the choroid. Am J Ophthalmol 1974;78:788-93.
28. Shammas H, Blodi F. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 1977;95:63-9.
29. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983;101:1894-9.
30. Diener-West M, Hawkins BS, Markowwitz JS, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110:245-50.
31. Coleman K, Baak JPA, Diest PV, Mullaney J, Farrell M, Fenton M. Prognostic factors following enculeation of 111 uveal melanomas. Br J Ophthalmol 1993;77:688-92.
32. McLean IW, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol 1977;95:48-58.
33. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR. Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol 1985;15:282-90.
34. Mclean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal-ciliary body melanoma: a multivariate survival analysis of tumour location. Ophthalmology 1995;102:1060-4.
35. Glynn RJ, Seddon JM, Gragoudas ES, Egan KM, Hart LJ. Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton irradiation of uveal melanoma. Ophthalmology 1989; 96:1566-73.
36. Callender GR. Malignant melanocytic tumors of the eye. Trans Am Acad Ophthalmol Otolaryngol 1931;36:131-42.
37. Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin 1962;2:387-402.
38. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Calender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
39. Augsburger JJ, Shields JA, Folberg R, et al. Fine needle aspiration biopsy in the diagnosis of intraocular cancer: cytologic-histologic correlations. Ophthalmology 1985;92:39-49.
40. Gass JDM. Problems in the differential diagnosis of choroidal nevi and malignant melanomas. Am J Ophthalmol 1977;83:299-323.
41. Gamel JW, McLean IW, Foster WD, Zimmerman LE. Uveal melanomas: correlation cytologic features with prognosis. Cancer 1978;41:1897-901.
42. Gamel JW, McLean I, Greenberg RA, Naids RM, Folberg R, Donoso LA, et al. Objective assessment of the malignant potential of intraocular melanomas with standard microslides stained with hematoxylin-eosin. Hum Pathol 1985;16:689-92.
43. Gamel JW, McLean IW, Greenberg RA, Zimmerman LE, Lichtenstein SJ. Computerised histologic assessment of malignant potential: a method for determining the prognosis of uveal melanomas. Hum Pathol 1982;13:893-7.
44. Gamel JW, McLean IW. Computerised histopathologic assessment of malignant potential. II. A practical method for predicting survival following enucleation for uveal melanoma. Cancer 1983;52:1032-8.
45. Gamel JW, McLean IW. Modern developments in histopathologic assessment of uveal melanomas. Ophthalmology 1984;91:679-84.
46. Donoso LA, Augsburger JJ, Shields JA, Greenberg RA, Gamel J. Metastatic uveal melanoma: correlation between survival time and cytomorphometry of primary tumors. Arch Ophthalmol 1986;104:76-8.
47. Huntington A, Haugan P, Gamel J, McLean I. A simple cytologic method for predicting the malignant potential of intraocular melanoma. Pathol Res Pract 1989;185:631-4.
48. McCurdy J, Gamel J, McLean I. A simple, efficient, and reproducible method for estimating the malignant potential of uveal melanoma from routine H&E slides. Pathol Res Pract 1991;187:1025-7.
49. Augsburger JJ. Fine needle aspiration biopsy of suspected metastatic cancers to the posterior uvea. Trans Am Ophthalmol Soc 1988;86:499-560.
50. Folberg R, Augsburger JJ, Gamel JW, Shields JA, Lang WR. Fine-needle aspirates of uveal melanomas and prognosis. Am J Ophthalmol 1985;100:654-7.
51. Char DH, Kroll SM, Stoloff A, Kaleta-Michaels S, Crawford JB, Miller TR, et al. Cytomorphometry of uveal melanoma: comparison of fine needle aspiration biopsy samples with histologic sections. Anal Quant Cytol Histol 1991;13:293-9.
52. Coleman DJ, Silverman RH, Rondeau MJ, Lizzi FL, McLean IW, Jakobiec FA. Correlations of acoustic tissue typing of malignant melanoma and histopathologic features as a predictor of death. Am J Ophthalmol 1990;110:380-8.
53. Srivastava A, Hughes LE, Woodcock JP, et al. Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour. Br J Cancer 1989;59:89-91.
54. Fallowfield ME, Cook MG. The vascularity of primary cutaneous melanoma. J Pathol 1991;164:241-4.
55. Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 1992;23:1298-305.
56. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100:1389-98.
57. Pe'er J, Rummelt V, Mawn L, Hwang T, Woolson RF, Folberg R. Mean of ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology 1994;101:1227-35.
58. Rummelt V, Folberg R, Woolson RF, Hwang T, Pe'er J. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology 1995;102:844-51.
59. Tannock IF, Hill RP. The basic science of oncology. New York: McGraw-Hill, 1992.
60. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
61. Yunis JJ, Brunning RD HR, Lobell M. High resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukaemia. N Engl J Med 1984;311:812-8.
62. Sisley K, Rennie IG, Cottam DW, Potter AM, Potter CW, Rees RC. Cytogenetic findings in six posterior uveal melanomas. Genes Chromosom Cancer 1990;2:205-9.
63. Rey JA, Bello MJ, De Compos JM, Ramos MC, Benitez J. Cytogenetic findings in a human malignant melanoma metastatic to the brain. Genes Chromosom Cancer 1985;16:179-83.
64. Griffin CA, Long PP, Schachat AP. Trisomy 6p in an ocular melanoma. Cancer Genet Cytogenet 1988; 32:129-32.
65. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-9.
66. Sisley K, Cottam DW, Rennie IG, Parsons MA, Potter AM, Potter CW, et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosom Cancer 1992; 5:197-200.
67. Horsthemke B, Prescher G, Bornfeld N, Becher R. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosom Cancer 1992;4:217-21.
68. Wiltshire RN, Elneer VM, Dennis T, Vine AK, Trent JM. Cytogenetic analysis of posterior uveal melanoma. Cancer Genet Cytogenet 1993;66:47-53.
69. Horsman DE, Sroka H, Rootman J, White VA. Monosomy 3 and isochromosome 8q in a uveal melanoma. Cancer Genet Cytogenet 1990;45:249-53.
70. Magauran RG, Gray B, Small KW. Chromosome 9 abnormality in choroidal melanoma. J Ophthalmol 1994;117:109-11.
71. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Cancer 1993;71:811-9.
72. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet 1995;80:40-6.
73. Sisley K, Rennie IG, Parsons MA, Rees RC. Cytogenetic alterations associated with advanced uveal melanomas. Invest Ophthalmol Vis Sci 1995;36:41.
74. Gordon KB, Thompson CT, Char DH, O'Brien JM, Kroll S, Ghazvini S, et al. Comparative genomic hybridisation in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res 1994;54:4764-8.
75. Speicher MR, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld N, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridisation. Cancer Res 1994; 54:3817-23.
76. Sisley K, Cottam D, Rennie IG, Potter AM, Rees RC. Cytogenetics of uveal melanoma. Invest Ophthalmol Vis Sci 1992;33:1243.
77. Prescher G, Bornfeld N, Horsthemke B, Becher R. Chromosomal aberrations defining uveal melanoma of poor prognosis [letter]. Lancet 1992;339:691-2.
78. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel K-H, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-5.
79. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, et al. Abnormalities of chromosomes 3 and 8, posterior uveal melanoma, a significant association with prognosis. Genes Chromosom Cancer 1997;18:1-7.
80. Ashley DJB. The two 'hit' and multiple 'hit' theories of carcinogenesis. Br J Cancer 1969;23:313-28.
81. Fearon ER, Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 1990;61:759-67.
82. Sisley K, Rennie IG, Rees RC. Comparison of the loss of heterozygosity of chromosome 3 markers between subsets of uveal melanomas. Invest Ophthalmol Vis Sci 1994;35:1928.
83. Chambers AF, Tuck AB. Oncogene transformation and metastatic phenotype. Anticancer Res 1988;9: 861-72.
84. Greenberg AH, Egan SE, Wright JA. Oncogenes and metastatic progression. Invasion Metastasis 1989; 9:360-78.
85. Royds JA, Sharrard RM, Parsons MA, Lawry J, Rees R, Cottam D, et al. c-myc oncogene expression in ocular melanomas. Graefes Arch Clin Exp Ophthalmol 1992;230:366-71.
86. Pepose JS, Holland GN, Wilhelmus KR. Ocular infection and immunity. St Louis: Mosby, 1996:157-82.
87. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen Van Der Eynde, Knuth A, et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
88. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, et al. Expression of MAGE genes in primary and metastatic melanoma. Int J Cancer 1995;63:375-80.
89. Brasseur F, Marchand M, Vanwuck R, Herin M, Lethe B, Chomez P, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52:839-41.
90. Russo V, Traverasi C, Verracchia A, Mottolese M, Natali PG, Bordigon C. Expression of the MAGE gene family in primary and metastatic breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 1995;64:216-21.
91. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of the MAGE genes by non-small cell lung carcinomas. Int J Cancer 1994;56:826-9.
92. Patard J-J, Brasseur F, Gil-Diez S, Radvanyi F, Marchand M, Francois P, et al. Expression of MAGE in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995;64:60-4.
93. Inoue H, Li J, Honda M, Nakashima H, Shibuta K, Arinaga S, et al. MAGE-1 mRNA expression in gastric carcinoma. Int J Cancer 1995;64:76-7.
94. Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Lienard D, Marchand M, et al. Infrequent expression of the MAGE gene family in uveal melanoma. Int J Cancer 1996;66:738-42.
95. Bakker ABH, Schreurs MWJ, De Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognised by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
96. Brichard V, Van Pel A, Wolfel T, Wolfel C, de Plaen E, Lethe B, et al. The tyrosinase gene codes for an antigen recognised by autologous cytotoxic lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95.
97. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognised by autologous cytotoxic lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
98. Jaeger E, Bernard H, Romero P, Ringhoffer M, Arand M, Karbach J, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma associated antigens. Int J Cancer 1996;66:162-9.